The US FDA Grants Breakthrough Device Designation to AbSolutions Med’s Rebuild Bioabsorbable Abdominal Wall Closure Device for Incisional Hernia
Shots:
- The company has received Breakthrough Device Designation from the US FDA for its Rebuild Bioabsorbable (REBUILD) abdominal wall closure device for incisional hernia
- REBUILD enables abdominal wall closure by distributing suture tension and maintaining midline fascial structure apposition during the healing process after surgery. It is absorbed to lower the long-term foreign body complication risk
- REBUILD is being investigated in a prospective, multicenter, single-arm trial for closure of the abdominal wall after oncologic laparotomy
Ref: AbSolutions Med | Image: AbSolutions Med
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
